26 Oct Gene responsible for relapses in young leukemia patients
One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia. This is what a study by Dr. Maja Krajinovic published in the Blood, the journal of the American Society of Hematology, reveals Dr. Krajinovic is an investigator at the Sainte-Justine University Hospital Research Center, which is affiliated with the University of Montreal.
Dr. Krajinovic’s team focused on asparaginase, one of the drugs in a chemotherapy “cocktail” administered to young patients during the intensification phase of their treatment.
They observed that E. coli asparaginase therapy was associated with an increase in relapses when administered to patients who had particular polymorphism (special form) of the ATF5 gene. In fact, this gene regulates asparagine synthetase, an enzyme that produces asparagine, which in turn feeds cancer cells.
“In the presence of this polymorphism that, as we demonstrated, modifies the transcription rate of the ATF5 gene, it is possible that the medication, rather than preventing the proliferation of leukemia cells by reducing the rate of asparagine, does just the opposite by creating feedback that triggers cancer cells to produce asparagine themselves,” explains Dr. Krajinovic.
The discovery of a form of gene associated with high rates of relapse during treatment with E.coli asparaginase opens the door to the possibility of selecting a type of pharmacological treatment based on a patient’s genetic profile, an approach that reflects the shift toward personalized medicine. “If a DNA test detects the implicated polymorphisms in children, it will be possible to predict the risk of relapse or side effects,” exclaimed Dr. Krajinovic. “The clinician can then propose an alternative treatment or adjust the dose accordingly.”
Since the introduction of combination chemotherapy, the rate of pediatric survival without relapse has skyrocketed to about 80%. Yet some patients still resist treatment or present side effects. Pharmacogenetic research strategies involve studying the reaction to each drug used for combined chemotherapy based on various patient genetic profiles so as to design treatment plans that increase efficacy and reduce side effects in patients. Dr. Krajinovic has published a number of similar studies that focus on antifolate, another drug used in combination regimens to treat acute lymphoblastic leukemia.
The study, led by Dr. Maja Krajinovic, an investigator in the Viral and Immune Disorders and Cancers research axis at the Sainte-Justine University Hospital Research Center and the Departments of Pediatrics and Pharmacology at the University of Montreal, was published online on the Oct. 4, 2011 in the scientific journal Blood. Dr. Daniel Sinnett, an investigator working in the same research axis, conducted with Dr. Krajinovic polymorphism-related functional assays. Dr. Sinnett is also an author of many studies on the genetic determinants of acute lymphoblastic leukemia, including a recent study on natural killer cells published in collaboration with Dr. Ali Ahmad as principal author. The study was published in the August 4, 2011, issue of Blood and was reviewed in an editorial that underscored the originality of the work.
The study was funded by the Canadian Institutes of Health Research (CIHR), the Leukemia and Lymphoma Society of Canada, the Charles Bruneau Foundation and the Fondation des Gouverneurs de l’espoir. Drs. Maja Krajinovic and Daniel Sinnett also held National researcher career award from the Fonds de recherche en santé du Québec (FRSQ) in conjunction with this work. The functional studies were conducted in part within the context of one of the projects of Genome Quebec and Genome Canada.
EurekAlert Public release date: 26-Oct-2011